Apricus Biosciences Signs Partnership With Scleroderma Research Foundation

(RTTNews) - Apricus Biosciences, Inc. (APRI), a pharmaceutical company, Friday announced a multi-year partnership agreement with the Scleroderma Research Foundation or SRF to support the foundation's activities and the further progress of its groundbreaking research programs.

Under the partnership, Apricus will co-sponsor an upcoming Scleroderma Research Roundtable Series and plans to participate in SRF's Annual Scientific Workshop and an SRF-sponsored event to take place at the upcoming American College of Rheumatology (ACR) 2014 Annual Meeting.

Scleroderma is an autoimmune disease characterized by widespread vascular abnormalities, immune dysregulation and fibrotic complications affecting multiple organs, including the skin. Scleroderma commonly leads to other medical conditions, such as Raynaud's phenomenon.

Apricus said its product candidate for the treatment of Raynaud's phenomenon, RayVa, is expected to begin a phase 2a clinical trial in the second half of 2014.